Skip to main content
Contact Us
Subscribe
E-Edition
52°
Site search
Search
Menu
Open user controls
Log In Using Your Account
Log In
Don't have an account?
Sign Up Today
My Account
Dashboard
Profile
Saved items
Logout
Home
About Us
Contact Us
Advertise
Terms and Conditions
Privacy Policy
Home Delivery
Subscription Services
Place an Ad
Promote Your Event
Local Weather
News
Sports
Entertainment
Obits
Multimedia
Photo Galleries
Videos
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Subscribe
Best of 2023
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Amphastar Pharma
(NQ:
AMPH
)
45.67
-0.22 (-0.48%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Jun 9, 2023
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Amphastar Pharma
< Previous
1
2
Next >
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
May 31, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2023
May 09, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2023
May 03, 2023
Via
ACCESSWIRE
Lilly to Divest BAQSIMI to Amphastar
April 24, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Business Update and Hold Conference Call on April 24th, 2023
April 24, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the 22nd Annual Needham Virtual Healthcare Conference
April 12, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended September 30, 2022
November 07, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended June 30, 2022
August 08, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals Receives FDA Approval for Naloxone Hydrochloride Nasal Spray 4mg
March 08, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on February 28, 2023
February 22, 2023
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Piper Sandler 34th Annual Healthcare Conference
November 22, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the 2022 Jefferies London Healthcare Conference
November 10, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release Third Quarter Earnings and Hold Conference Call on November 7, 2022
October 28, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Present at the Wells Fargo 2022 Healthcare Conference
September 02, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals Receives FDA Approval for Epinephrine Pre-Filled Syringes
August 16, 2022
Via
ACCESSWIRE
Amphastar Pharmaceuticals to Release Second Quarter Earnings and Hold Conference Call on August 8, 2022
August 01, 2022
Via
ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
July 19, 2022
Via
ACCESSWIRE
Amphastar Receives FDA Approval for Vasopressin
July 19, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / July 19, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Amphastar Pharmaceuticals to Present at the Jefferies Healthcare Conference
June 06, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / June 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, and Dan Dischner, V.P of Corporate...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
June 06, 2022
Via
AB Newswire
Amphastar Receives FDA Approval for Regadenoson
May 24, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / May 24, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated New...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Amphastar Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2022
May 09, 2022
Reports Net Revenues of $120.4 Million for the Three Months Ended March 31, 2022 RANCHO CUCAMONGA, CA / ACCESSWIRE / May 9, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or the...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Amphastar Pharmaceuticals to Release First Quarter Earnings and Hold Conference Call on May 9, 2022
May 02, 2022
Our newswire features a comprehensive, flat-fee Press Release service. Generate quality engagement with real-time analytics to improve visibility and expand your influence.
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Amphastar Receives FDA Approval for Ganirelix Acetate Injection
April 08, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 8, 2022 / Amphastar Pharmaceuticals, Inc., (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has approved the Company's Abbreviated...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Amphastar Pharmaceuticals to Present at the 21st Annual Needham Virtual Healthcare Conference
April 06, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / April 6, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Amphastar Pharmaceuticals Reports Financial Results for the Three Months and Full-Year Ended December 31, 2021
March 10, 2022
Reports Net Revenues of $120.9 Million for the Three Months Ended December 31, 2021 RANCHO CUCAMONGA, CA / ACCESSWIRE / March 10, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) ("Amphastar" or...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Amphastar Pharmaceuticals to Release Fourth Quarter Earnings and Hold Conference Call on March 10th, 2022
March 03, 2022
RANCHO CUCAMONGA, CA / ACCESSWIRE / March 3, 2022 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the Company will release results for its fourth quarter of 2021 ended December 31, 2021,...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Amphastar Receives FDA Tentative Approval for Vasopressin
December 29, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / December 29, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced that the U.S. Food and Drug Administration ("FDA") has tentatively approved the Company's...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Exposures
Product Safety
Amphastar Pharmaceuticals to Present at the Piper Sandler 33rd Annual Virtual Healthcare Conference
November 22, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 22, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
Amphastar Pharmaceuticals to Present at the Jefferies London Healthcare Conference
November 11, 2021
RANCHO CUCAMONGA, CA / ACCESSWIRE / November 11, 2021 / Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) announced today that Bill Peters, Executive V.P. and CFO, Dan Dischner, V.P of Corporate...
From
Amphastar Pharmaceuticals, Inc.
Via
AccessWire
Topics
Regulatory Compliance
Exposures
Legal
Regulatory
< Previous
1
2
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.